LATEST BLOG ARTICLES
VIEW ALL →Iambic Therapeutics prepares for Nasdaq IPO, joining the AI drug-discovery wave
Iambic Therapeutics plans an IPO, strengthening the AI-driven drug discovery sector on Nasdaq.
TechCrunch Founder Summit 2023: Insights on fundraising, hiring, and AI in Boston
Discover key insights on fundraising, hiring, and AI at the TechCrunch Founder Summit in Boston on November 4, 2023.
Edward Goldthorpe increases stake in Runway Growth Finance with $67,450 stock purchase
Edward Goldthorpe of Runway Growth Finance invests $67,450 in company stock, signaling confidence in growth prospects.
Fed signals more rate hikes necessary to combat inflation
Fed officials indicate additional rate hikes are essential to tackle persistent inflation challenges.
Bamboo Insurance Services delays IPO amid market challenges
Bamboo Insurance Services has postponed its IPO due to current market conditions, according to Bloomberg reports.
NSE IPO attracts record ₹90,000 crore demand, setting new subscription benchmarks
NSE IPO garners ₹90,000 crore in bids, marking a milestone among India's largest public offerings.
Coinbase democratizes access to IPOs through Oura partnership
Coinbase partners with Oura to open IPO allocations for US retail investors, enhancing access to public markets.
Jamie Dimon projects AI spending by hyperscalers to reach $1 trillion in 2024
JPMorgan CEO Jamie Dimon forecasts hyperscaler AI investments could soar to $1 trillion next year, fueling economic growth and inflation concerns.
Assessing the muted retail response to NSE's ₹22,562 crore IPO
Explore the factors behind the lukewarm retail interest in NSE's record IPO of ₹22,562 crore.
Iambic Therapeutics aims for IPO with Nvidia support
Iambic Therapeutics files for IPO, supported by Nvidia, advancing AI in drug development.
Federal Reserve's stance on inflation drives interest rate increase
Insights into the Federal Reserve's interest rate decisions amid ongoing inflation concerns.
Iambic Therapeutics pursues IPO as biotech sector gains momentum
Iambic Therapeutics, backed by QIA, aims for US IPO amid a thriving biotech market.